Prothena Corporation plc is a late-stage clinical biotechnology company focused on protein dysregulation, developing therapies for neurodegenerative and rare peripheral amyloid diseases. Its pipeline includes prasinezumab (Parkinson's disease), coramitug (ATTR amyloidosis), BMS-986446 (Alzheimer's disease), and PRX019 (neurodegenerative diseases). The company also develops CYTOPE technology targeting intracellular disease pathways and PRX012, an anti-amyloid beta antibody. Programs are both wholly-owned and partnered with Roche, Novo Nordisk, and Bristol Myers Squibb.
Q2 FY2026 — expected 2026-08-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-27 | 2025-12-31 | 0001559053-26-000008 | EDGAR | 75K words |
| 2025-02-27 | 2024-12-31 | 0001559053-25-000009 | EDGAR | 82K words |
| 2024-02-22 | 2023-12-31 | 0001559053-24-000008 | EDGAR | 80K words |
| 2023-02-28 | 2022-12-31 | 0001559053-23-000005 | EDGAR | 84K words |
| 2022-02-25 | 2021-12-31 | 0001559053-22-000008 | EDGAR | — |
| 2021-02-26 | 2020-12-31 | 0001559053-21-000008 | EDGAR | — |
| 2020-03-03 | 2019-12-31 | 0001559053-20-000005 | EDGAR | — |
| 2019-03-15 | 2018-12-31 | 0001559053-19-000007 | EDGAR | — |
| 2018-02-26 | 2017-12-31 | 0001559053-18-000008 | EDGAR | — |
| 2017-02-27 | 2016-12-31 | 0001559053-17-000005 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001559053-26-000022 | EDGAR | 52K words |
| 2025-11-06 | 2025-09-30 | 0001559053-25-000044 | EDGAR | 53K words |
| 2025-08-04 | 2025-06-30 | 0001559053-25-000031 | EDGAR | 53K words |
| 2025-05-08 | 2025-03-31 | 0001559053-25-000023 | EDGAR | 53K words |
| 2024-11-12 | 2024-09-30 | 0001559053-24-000032 | EDGAR | 54K words |
| 2024-08-08 | 2024-06-30 | 0001559053-24-000025 | EDGAR | 54K words |
| 2024-05-08 | 2024-03-31 | 0001559053-24-000014 | EDGAR | 53K words |
| 2023-11-02 | 2023-09-30 | 0001559053-23-000033 | EDGAR | 56K words |
| 2023-08-03 | 2023-06-30 | 0001559053-23-000026 | EDGAR | 55K words |
| 2023-05-04 | 2023-03-31 | 0001559053-23-000016 | EDGAR | 53K words |
| 2022-11-03 | 2022-09-30 | 0001559053-22-000045 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001559053-22-000032 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001559053-26-000021 | EDGAR | 3K words |
| 2026-02-27 | 0001559053-26-000009 | EDGAR | 1K words |
| 2026-02-19 | 0001559053-26-000003 | EDGAR | 3K words |
| 2025-12-12 | 0001559053-25-000049 | EDGAR | 1K words |
| 2025-11-19 | 0001559053-25-000047 | EDGAR | 1K words |
| 2025-11-06 | 0001559053-25-000042 | EDGAR | 3K words |
| 2025-08-27 | 0001193125-25-189765 | EDGAR | 2K words |
| 2025-08-06 | 0001193125-25-174061 | EDGAR | 1K words |
| 2025-08-04 | 0001559053-25-000029 | EDGAR | 3K words |
| 2025-07-30 | 0001193125-25-169367 | EDGAR | 9K words |
247 total filings indexed. 215 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001559053 |
| Ticker | PRTA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | L2 |
| Website | https://www.prothena.com |
| Listed | 2012-12-18 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/PRTA (~200 tokens, structured JSON with cryptographic provenance)